Advantia Health Partners with Mirvie to Bring Predictive and Preventive Care to Maternal Health
ARLINGTON, Va. & WASHINGTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Mirvie, Inc., in partnership with Advantia Health, has launched a first-of-its-kind pilot program in the U.S. to improve pregnancy outcomes. The program uses the clinically validated Encompass Preeclampsia Test (powered by the Mirvie RNA Platform) to assess high and low risk for preeclampsia, enabling clinicians to initiate preventive care for the appropriate patients.
The potential to impact pregnancy health is huge. We have been operating without objective data. This test allows us to identify and focus on the few patients at truly high risk with a preventive care plan.
Share
Preeclampsia, a dangerous pregnancy complication, has nearly doubled in recent years and now affects 1 in 12 pregnancies, costing the U.S. healthcare system billions each year. Current risk assessment methods have proved ineffective, leading to high rates of preterm deliveries, neonatal ICU admissions, and preventable deaths.
'The potential to impact pregnancy health is huge. We have been operating without objective data. This test allows us to identify and focus on the few patients at truly high risk with a preventive care plan," said Dr. Jo'Ann Jackson, Regional Chief Medical Officer of the Mid-Atlantic, Advantia Health.
'Until now, we have lacked an effective and objective test to assess risk for preeclampsia in patients with no known risk factors. The Encompass test helps resolve this ambiguity of risk, ensuring the right pregnancies get the right preventive care. We are bringing a level of personalized care, based on molecular signatures, that has been long available in oncology, but for the first time can now be brought to pregnancy care,' said Dr. Thomas McElrath, Vice President of Clinical Development at Mirvie, and practicing physician in Maternal Fetal Medicine at Brigham and Women's.
"We know innovations in maternal health are needed," said Dr. Michael Udwin, Medical Director, CareFirst BlueCross BlueShield (CareFirst). 'We are excited about the potential for improved outcomes for both mother and baby through Mirvie's collaboration with Advantia Health, which provides care to many CareFirst members.'
This year-long collaboration, which launches immediately, reflects Advantia Health's commitment to improving pregnancy outcomes in the mid-Atlantic region and Mirvie's commitment to bringing a precise standard of care to pregnancy health.
About Mirvie
Mirvie is bringing scientifically rigorous and data-driven approaches to solving some of the most pressing clinical problems in women's health, beginning with pregnancy. Serious complications impact one in five pregnancies in the U.S., and Mirvie is committed to creating a world where every pregnancy is as safe and healthy as possible. Founded and led by a team of seasoned entrepreneurs and scientists, the company is based in South San Francisco, California and backed by top-tier investors, including Blackrock, Decheng Capital, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield. For more information, visit Mirvie.com.
About Advantia Health
Advantia Health is transforming healthcare for all women by setting a higher standard of care and convenience, while reducing unnecessary costs. Compassion and value inspire everything we do. We take time to listen, answer questions completely, and offer helpful technology between visits so that our patients are empowered and at ease. More than 140 Advantia Health providers serve over 250,000 patients at our specialist offices. Learn more at advantiahealth.com
About CareFirst BlueCross BlueShield
In its 87th year of service, CareFirst, an independent licensee of the Blue Cross and Blue Shield Association, is a not-for-profit healthcare company which, through its affiliates and subsidiaries, offers a comprehensive portfolio of health insurance products and administrative services to 3.5 million individuals and employers in Maryland, the District of Columbia and Northern Virginia. In 2023, CareFirst infused $233 million in support of regional community impact to improve overall health and advance accessible, affordable, equitable, high-quality healthcare. To learn more about CareFirst BlueCross BlueShield, visit www.carefirst.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
10 hours ago
- Forbes
How Two Fathers Turned Personal Crisis Into Preeclampsia Innovation
Left to right: Mirvie management team: Maneesh Jain, cofounder and CEO, Michal Elovitz, MD and Chief ... More Medical Advisor, Steve Quake, PhD and cofounder When Maneesh Jain's wife went into what was supposed to be routine labor nearly 20 years ago, he was shocked by how quickly everything unraveled. 'It went from a normal pregnancy to an emergency C-section in a matter of minutes,' he recalled. 'And I was left wondering, how is it that we know so little about something that matters so much?' For Dr. Steve Quake, a similar moment came when his first daughter was born a month early. 'It really shook me,' he said. 'That's what drew me into maternal and fetal health. At the time, we had an amniocentesis done—and that's what started me down the path to develop non-invasive prenatal testing (NIPT).' Both men, scientists by training and fathers by life experience, were driven by their daughters' births to solve one of medicine's most neglected problems: the inability to predict serious pregnancy complications before they strike. In 2018, they co-founded Mirvie, a company that uses RNA technology to anticipate and prevent preeclampsia, a condition that affects one in 12 pregnancies and can lead to seizures, organ failure, and even death. Their work has helped shift the model of maternal care from a reactive to a proactive approach. Despite advancements in maternal care, preeclampsia remains one of the most dangerous pregnancy complications in the U.S. and globally. The global preeclampsia diagnostics market is expected to grow substantially, rising from $2.2 billion in 2024 to $5.8 billion by 2034. The preeclampsia laboratory testing market is valued at $16.3 billion in 2024 and is projected to nearly double to $31.4 billion by 2032. The current screening tools rely heavily on maternal age, BMI, race, and family history—imprecise proxies that leave both patients and physicians 'flying blind,' said Jain, CEO at Mirvie. The consequences are not just short-term. Research shows that preeclampsia can result in long-term health complications for both mothers and babies, including increased risks of cardiovascular disease, kidney disease, and developmental challenges in children. preeclampsia-related medical costs in the U.S. alone total an estimated $2.18 billion in the first year after birth—$1.03 billion for maternal care and $1.15 billion for infant care. 'It's nearly impossible to pinpoint who will develop preeclampsia,' said Dr. Dallas Reed, a medical geneticist at Tufts Medicine and a member of Mirvie's clinical advisory board. 'The risk factors are too broad to be meaningful. As a result, care physicians struggle to have focused, proactive conversations about this serious condition, because nearly every pregnant woman qualifies as 'at risk.'' Mirvie's solution is Encompass, a simple blood test that can be taken at home around 18 weeks of gestation, aligned with the fetal anatomy scan, to detect molecular signatures that predict preeclampsia well before symptoms emerge. In a groundbreaking study involving over 10,000 pregnancies, Encompass was able to identify 91% of women who went on to develop preterm preeclampsia. Those identified as low-risk had a 99.7% likelihood of not developing the condition. 'What's revolutionary here is that the signal comes from RNA, which tells us what's happening in real-time during pregnancy—not what you inherited, but what your body is doing,' said Quake. 'It gives us a biological window into the future.' Reed added, 'That's why I'm so excited about Mirvie's Encompass test. For the first time, we can offer pregnant people a clear, personalized assessment of their preeclampsia risk—early enough to make a real difference. Encompass empowers us to deliver timely, individualized care to the patients who need it most.' Recognizing that diagnosis is only the first step, Mirvie took it a step further. The company sponsored the first multi-stakeholder, patient-centered care plan to prevent preeclampsia, published in the American Journal of Obstetrics and Gynecology in 2023. Created with input from OB-GYNs, midwives, doulas, nurses, and patients, the care plan outlines practical, evidence-based steps—such as taking low-dose aspirin, monitoring blood pressure, and making key lifestyle adjustments. It's designed to help both patients and providers feel more prepared and confident when managing the risks associated with preeclampsia. 'We heard from OBs that the test alone wasn't enough—they needed to know what to do with the results,' said Jain. 'So we created a comprehensive action plan that brings everyone to the table.' While Jain and Quake acknowledge the historical imbalance in who gets heard in healthcare conversations, they view their role not as replacing women's voices but amplifying them. 'One of the challenges in women's health is that it's often marginalized—treated as a niche,' said Jain. 'But this isn't just a women's issue. It's a family issue. If a mom has preeclampsia, that affects the baby's lifelong health, too.' Quake added: 'This is a problem that touched both of our lives. We didn't take it on out of theory. We took it on for the sake of our families.' They've built Mirvie with that philosophy in mind: The company is majority women, empathy is a core corporate value, and product development involves constant feedback from patients and OB-GYNs. 'We've spoken with thousands of pregnant people and providers,' said Jain. 'Everything we've built reflects what they told us they needed.' Mirvie has raised over $75 million in venture capital funding. It also received a $4.6 million grant from the Bill & Melinda Gates Foundation to study the effectiveness of RNA-based testing in Sub-Saharan Africa, with research sites in Ghana, Cameroon, and Zambia. 'Being impacted by serious complications in both my pregnancies, it was just so clear to me that a company like Mirvie needs to exist,' said Holly Maloney, managing director at General Catalyst. 'We must shift the paradigm from reactive to proactive prenatal care to improve outcomes.' Still, maternal health remains vastly underfunded. Between 2019 and 2024, investment in women's health grew by 200%, but it still accounts for only about 2% of all healthcare investment. Jain believes that's starting to change. 'We've seen that when you present hard data and real-world impact, investors take notice,' he said. 'But we still need to make the case that this isn't niche—it's fundamental. It's about healthier families and healthier futures.' This Father's Day, Jain and Quake are proof that parenthood doesn't just change lives—it can help save them. What began as fear in a delivery room has turned into a mission to protect millions of families from the dangers of preeclampsia. With science, empathy, and a deep commitment to change, these two dads are giving maternal health the attention—and innovation—it deserves.
Newsweek
a day ago
- Newsweek
Aldi Products Recalled in 16 States: Full List of Items Impacted
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. There are currently two recalls of food products sold at Aldi, according to Aldi and the U.S. Food and Drug Administration (FDA), impacting multiple states. This is what to know about the recalls. In response to a request for comment on this article, Aldi directed Newsweek to their product recall page, which states: "While ALDI is committed to providing only the best quality at the lowest prices, our top priority is the safety of you and your family. From developing stringent standards to working with trusted manufacturers on product quality and testing, every measure possible is taken to fulfill that promise." Why It Matters Food recalls are initiated when a product is deemed to have the potential to adversely affect a person when consumed. The most common reason for food recalls is undeclared allergens. An Aldi grocery store is pictures on May 02, 2025 in Washington, DC. An Aldi grocery store is pictures on May 02, 2025 in Washington, are nine major allergens, including soybeans, wheat, sesame, milk, eggs, fish, crustacean shellfish, tree nuts and peanuts. For customers with allergies to these allergens, consumption of food contaminated with or containing them can cause severe and even life-threatening reactions. Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream Recall On June 4, the U.S. Food and Drug Administration (FDA) and Aldi announced a recall of Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream due to the potential presence of an undeclared milk allergen. The product is supplied by Camerican International which voluntarily issued the recall. The product was sold at ALDI stores in the following states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina and Tennessee. The recalled product was distributed in 7.05-ounce cardboard boxes with the UPC Code 4061459561807 and "Best If Used By" date of July 14, 2026, printed on the label. No illnesses or allergic reactions were reported as of June 4, 2025. Consumers with milk allergies are urged not to consume the product and to return it to Aldi for a full refund. Newsweek has reached out to Camerican International via email for comment. Atlantic Salmon Portions with Seafood Stuffing Recall Atlantic Salmon Portions with Seafood Stuffing, manufactured by Santa Monica Seafood of Rancho Dominguez, were recalled on May 27, 2025, after it was found that the product may contain undeclared soy. The recalled product was available at Aldi locations in California, Nevada and Arizona. As of May 27, no illnesses had been reported, as per an FDA press release. The product was distributed in 16oz packaging with the UPC Code 4061459716313 and the use/freeze-by date of June 2, 2025. Newsweek has reached out to Santa Monica Seafood via email for comment. What People Are Saying Dr. Sebastian Lighvani, director of New York Allergy & Asthma PLLC, previously told Newsweek: "The difference between someone who is allergic and someone who's not, really, at its core is that an allergic individual can come across something as innocuous as a small amount of the food, egg, peanut, milk, and ingest it. "And while a normal person will just digest that and process it, an allergic person actually sees this as a foreign threat. And that triggers the allergic response, which can initially be associated with activation of what we think are these antibodies called IgE antibodies that recognize specifically that piece of food, be it protein or egg protein. And that then triggers these cells, called the mast cells, to release all these inflammatory mediators, like histamine and other kinds of mediators, like nutrients, which can have kind of profound effects." What Happens Next Affected customers should return recalled products to Aldi for a full refund.
Yahoo
5 days ago
- Yahoo
Chillicothe girl with brain injury from flu complications returns home
CHILLICOTHE, Ohio (WCMH) — A Chillicothe family is grateful to have their little girl back home, but now they have a long and expensive road ahead of them. NBC4 first reported on Locklynn Boler at the beginning of March. At just 4 years old, she fell into a coma for weeks due to severe complications from the flu. She has fortunately recovered from it, but will never be the same again due to the brain injury she suffered from the coma. 'You see all these kids dying from this, and somehow she made it,' said Bradley Boler, Locklynn's father. That's because Locklynn was born a fighter. 'She's been through it since the day she was born,' Boler said. 'She had issues with her kidneys well before all of this.' Boler said its been a constant battle since Locklynn woke up from her coma. Her brain injury has left her unable to walk, talk or eat on her own. Since then, she's been in and out of Nationwide Children's Hospital. 'She's on like 20 different meds,' Boler said. 'She takes a massive med pass at 8 p.m. and 8 a.m. She has to get vest treatments multiple times a day.' The bills have been piling up for the Boler family. They're in the process of making their home wheelchair-accessible for Locklynn. 'The plan now is we wound up getting a van finally,' Boler said. 'We want to try to get one with a lift, as well as getting another ramp built on to the back porch.' Locklynn now needs around-the-clock care. One of the Boler family's biggest struggles was finding a nurse, but their prayers have been answered. 'My sister quit her job to take care of Locklynn,' Boler said. 'We owe her the world.' Boler said they're grateful for the outpouring of love and support from the community. Fundraisers for their family have brought in close to $11,000. All of that money is being put toward necessary modifications to make Locklynn as comfortable as possible as she adapts to her new normal. Local organizations like the Mid-Ohio Board for an Independent Living Environment (MOBILE) have also stepped up to provide resources. 'Value your time with your kids,' Boler said. 'I spent a lot of the last year working 70 to 80 hours a week. Spend more time with your kids. You never know. It could happen to anybody.' While Locklynn will never be the little girl her family once knew, they said they love this new version of her just as much. 'She's amazing,' Boler said. 'That's all I can say. She's the strongest kid I've ever met in my life.' The Boler family is still raising funds to be able to make the necessary modifications to their home for Locklynn. They're selling #LocklynnStrong t-shirts. You can purchase one here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
